India : The Drugs Controller General of India (DCGI) has granted permission to Mumbai-based pharmaceutical company Cipla to import Moderna’s Covid-19 vaccine for restricted emergency use in the country. “This permission is for restricted use in emergency situations in the public interest. The firm has to submit 7 days’ safety assessment of the vaccine in the first 100 beneficiaries before rolling out of the vaccine for further immunisation programme, according to the approval order,” news agency PTI quoted an official as saying.
Moderna’s vaccine is the fourth COVID-19 jab to be available in India after Covishield, Covaxin and Sputnik.
The Moderna vaccine has been shown to have an efficacy of approximately 94.1% in protecting against Covid-19. The immunity starts to develop after 14 days of the first dose, WHO mentions on its site.
The strategic advisory group of experts (SAGE) recommends the use of the Moderna mRNA-1273 vaccine at a schedule of two doses (100 µg, 0.5 ml each) 28 days apart. If necessary, the interval between the doses may be extended to 42 days. Compliance with the full schedule is recommended and the same product should be used for both doses. The Moderna vaccine is a two-dose regimen at an interval of 28 days. In India as well, it will be administered in two doses, Paul confirmed in the briefing. However, the interval between the two doses in India is yet to be announced.